GSK•benzinga•
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
Summary
GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga